Passive Immunotherapy of Cynomolgus Monkeys with Anti-Rotavirus IgY
-
Published:2024-08-30
Issue:9
Volume:16
Page:1149
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Bentes Gentil Arthur1ORCID, Guimarães Juliana Rodrigues1, Volotão Eduardo de Mello2, Lanzarini Natália Maria12ORCID, da Silva Alexandre dos Santos1, Gardinali Noemi Rovaris1, Marchevsky Renato Sergio3, Leite José Paulo Gagliardi2, de Oliveira Jaqueline Mendes1ORCID, Pinto Marcelo Alves1ORCID
Affiliation:
1. Laboratório de Desenvolvimento Tecnológico em Virologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil 2. Laboratório de Virologia Comparada e Ambiental, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil 3. Laboratório de Ensaios Pré-Clínicos, Instituto de Tecnologia em Imunobiológicos, Fiocruz, Rio de Janeiro 21040-360, RJ, Brazil
Abstract
Immunoglobulins Y (IgY) purified from egg yolks of hens represents an attractive, cost-effective alternative for the development of new diagnostic and therapeutic platforms. In this study, we evaluated the therapeutic efficacy of rotavirus-specific IgY in a cynomolgus monkey (Macaca fascicularis) model. Animals were experimentally infected with human rotavirus Group A (RVA), the most common cause of severe acute diarrhoea among young children worldwide. Animals were administered human RVA (3.1 × 107 FFU/mL) by oral gavage, challenged with 2.5 mg of anti-RVA IgY orally, and monitored for five days according to clinical, haematological and biochemical parameters; serum electrolyte levels; viral shedding; and histopathological changes. Immunotherapy with anti-RVA IgY had a protective effect against severe rotavirus-induced enteritis in four of the ten treated monkeys, as evidenced by histopathological findings. Although only one animal had diarrhoea, all but one exhibited virus shedding regardless of the treatment.
Funder
National Council for Scientific and Technological Development Carlos Chagas Filho Foundation for Research Support of Rio de Janeiro State Oswaldo Cruz Institute
Reference66 articles.
1. GBD 2016 Diarrhoeal Disease Collaborators (2018). Estimates of the Global, Regional, and National Morbidity, Mortality, and Aetiologies of Diarrhoea in 195 Countries: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis., 18, 1211–1228. 2. (2024, February 16). Rotavirus—PAHO/WHO|Pan American Health Organization. Available online: https://www.paho.org/en/topics/rotavirus. 3. Gutierrez, M.B., Fialho, A.M., Maranhão, A.G., Malta, F.C., da Silva Ribeiro de Andrade, J., de Assis, R.M.S., da Silva e Mouta, S., Miagostovich, M.P., Leite, J.P.G., and Fumian, T.M. (2020). Rotavirus A in Brazil: Molecular Epidemiology and Surveillance during 2018–2019. Pathogens, 9. 4. Genetic Variability of Human Rotavirus Strains Isolated from Eastern and Northern India;Das;J. Med. Virol.,2004 5. Mao, T., Wang, M., Wang, J., Ma, Y., Liu, X., Wang, M., Sun, X., Li, L., Li, H., and Zhang, Q. (2022). Phylogenetic Analysis of the Viral Proteins VP4/VP7 of Circulating Human Rotavirus Strains in China from 2016 to 2019 and Comparison of Their Antigenic Epitopes with Those of Vaccine Strains. Front. Cell. Infect. Microbiol., 12.
|
|